Sociodemographic, clinical, and immunological factors associated with SARS-CoV-2 diagnosis and severe COVID-19 outcomes in people living with HIV: a retrospective cohort studyDaniel K. Nomah, Bibiana Morell, Daniel Podzamczer et al.|The Lancet HIV|2021Cited by 110
Dual Therapy With Darunavir and Ritonavir Plus Lamivudine vs Triple Therapy With Darunavir and Ritonavir Plus Tenofovir Disoproxil Fumarate and Emtricitabine or Abacavir and Lamivudine for Maintenance of Human Immunodeficiency Virus Type 1 Viral Suppression: Randomized, Open-Label, Noninferiority DUAL-GESIDA 8014-RIS-EST45 TrialFederico Pulido, M. A. von Wichmann, Esteban Ribera et al.|Clinical Infectious Diseases|2017Cited by 103
Strategies to reengage patients lost to follow up in HIV care in high income countries, a scoping reviewJorge Palacio‐Vieira, Eva González‐Roca, Juliana Reyes‐Urueña et al.|BMC Public Health|2021Cited by 37
Mortality and immunovirological outcomes in patients with advanced HIV disease on their first antiretroviral treatment: differential impact of antiretroviral regimensJoaquín Burgos, Jorge Palacio, Sergio Moreno‐Fornés et al.|Journal of Antimicrobial Chemotherapy|2022Cited by 22
Impact of tenofovir on SARS-CoV-2 infection and severe outcomes among people living with HIV: a propensity score-matched studyDaniel K. Nomah, Maribel Tamayo, Juliana Reyes‐Urueña et al.|Journal of Antimicrobial Chemotherapy|2022Cited by 20